The U.S. currently uses five COVID-19 vaccines from Pfizer, Moderna, and Novavax. All are safe and effective against the coronavirus, especially in preventing hospitalization and death.

The Centers for Disease Control and Prevention (CDC)Trusted Source recommends that everyone ages 6 months and older get an annual COVID-19 vaccine.

There are two types of COVID-19 vaccines available: mRNA and protein subunit vaccines. mRNA stands for messenger RNA, which is part of DNA that tells cells how to produce proteins. mRNA vaccines work by using mRNA to tell your body how to make part of the protein in the virus that causes COVID-19. You can’t get COVID-19 from these proteins, but your body can make antibodies to fight the virus when these proteins are present.

Protein subunit vaccines use a part of the virus that causes COVID-19. Since it’s only part of the virus, you can’t get COVID-19 from it, but it stimulates your body to produce antibodies that fight the virus and help prevent you from getting COVID-19 or help you have milder symptoms if you do get it.

Both types have been found to be effective. The CDC recommends the 2024-2025 versions for all COVID-19 vaccines because these vaccines are made for the most recent variants of the SARS-CoV-2 virus (which causes COVID-19).

You may wonder which of these vaccines is best for you. The answer depends on many factors, including your age and overall health, but according to the CDC, they do not recommend any one COVID-19 vaccine over another when more than one vaccine is available for you based on your age and health.

Read on to learn more about the CDC-recommended vaccination schedule for each approved vaccine and which may be best for you.

The following summary shows the latest CDC vaccination guidelines for the five currently approved COVID-19 vaccines in the United States for individuals who are not moderately or severely immunocompromised. That means you do not have health conditions that make you more likely to have serious reactions to infections and other health events.

Data is based on the 2024 to 2025 vaccination guidance from the CDCTrusted Source. Be sure to speak with the healthcare professional who gives you your COVID-19 vaccination. They can let you know if you need more than one COVID-19 vaccination and when you need to have it.

2024–2025 Pfizer-BioNTech
COVID-19 Vaccine
(mRNA vaccines):
Pfizer (6 months to 11 years old) and COMIRNATY (12 years old and older)
2024-25 Vaccinations
Moderna (mRNA vaccines):
Moderna (6 months to 11 years old) and SPIKEVAX (12 years old and older)
2024-25 Vaccinations
Novavax (protein subunit vaccine)
2024-25 Vaccinations
Recommended ages6 months old and older6 months old and older12 years old and older
Primary series
1 initial dose:

6 months to 11 years:
• dose 1 – initial dose (1 booster later)

5 years and older:
• 1 dose only (no booster needed)


1 or 2 initial doses:

6 months to 4 years:
• dose 1 now

5 years to 64 years:
• only 1 dose needed for individuals who are 6 months to 64 years old and who have a 2024–25 mRNA COVID-19 vaccination

Over 65 years old:
• 1 initial vaccination (and 1 booster to follow)
1 initial dose:

12 years old and older: • dose 1 – initial dose
Booster doseBooster (dose 2):

6 months to 11 years:
• dose 2 given at least 4 to 8 weeks after Dose 1

Over 65 years old:
• dose 2 given at 4 months after dose 1
Booster (dose 2):

6 months to 4 years:
• dose 2 – 4 to 8 weeks after dose 1 of any type of mRNA vaccination

5 years to 64 years:
• No dose 2 needed for individuals who are 4 years to 64 years old and who have a 2024–25 mRNA COVID-19 vaccination
(CDC does not recommend any COVID-19 vaccination except the 2024-25 versions.)

Over 65 years old:
•needs to have 2 doses of a 2024-25 mRNA COVID-19 Vaccination, regardless of COVID-19 Vaccination history
• dose 2 given 6 months after dose 1 of a 2024-25 mRNA COVID-19 Vaccination
Booster (dose 2):

dose 2 given 6 months after dose 1

When COVID-19 vaccines were first introduced, the general rule of thumb was that the best vaccine was the one that you could get. However, at the beginning of 2022, the CDCTrusted Source updated its vaccine recommendations to state that the two mRNA vaccines — Pfizer and Moderna — were preferred over the Johnson & Johnson (J&J) vaccine.

The J&J vaccine has since been discontinued. In 2023, the Food and Drug Administration (FDA)Trusted Source authorized a protein subunit vaccine called Novavax.

Today, the CDC recommendsTrusted Source five COVID-19 vaccines: four mRNA: two from Moderna and two from Pfizer-BioNTech, and one protein subunit vaccine from Novavax. The CDC only recommends the 2024-25 versions of COVID-19 vaccinations.

You’ll need to follow the dosing schedule for the specific vaccination you choose.

So, which is better for you and your health situation?

mRNA vaccines: Is Pfizer or Moderna better?

MRNA vaccines tell your body how to make the necessary protein to fight a virus. Clinical trials for the two mRNA vaccines found that both Pfizer and Moderna were safe and had similar effectiveness: 95% for Pfizer and 94.1% for Moderna.

The similar effectiveness of these vaccines also extends into a real-world setting.

A 2022 study examined vaccine effectiveness in U.S. veterans vaccinated between January and May 2021. While the two vaccines were comparable, the Moderna vaccine prevented symptomatic infection and hospitalization slightly more effectively than the Pfizer vaccine.

Note that the effectiveness of the Pfizer and Moderna vaccines may vary depending on the coronavirus variant.

For example, a 2022 study of the Pfizer vaccine against the Omicron variant found that vaccine effectiveness was 67.2% in the 2 to 4 weeks after a booster but declined to 45.7% after 10 or more weeks.

Another 2022 studyTrusted Source of the Moderna vaccine against the Omicron variant found that vaccine effectiveness was 71.6% in the 14 to 60 days after a booster but declined to 47.4% after 60 days.

That said, the FDATrusted Source now approves updated versions of these vaccines annually to target newer virus variants.

Protein subunit vaccine: Is Novavax better than the mRNA vaccines?

Protein subunit vaccines are a direct injection of a modified protein that stimulates the immune system to make antibodies and T cells to fight a virus.

A 2023 study compared the effectiveness of mRNA and protein subunit vaccines. Researchers found that all the newer vaccines are at least 90% effective regardless of how they work.

However, a 2023 study suggests that Novavax may cause fewer side effects than mRNA vaccines.

Some research suggests that mixing mRNA and protein subunit vaccines might result in a better immune response and, therefore, better protection. For example, a 2023 animal studyTrusted Source in mice examined mixing mRNA and protein subunit vaccines against influenza strains and found good effectiveness.

However, the CDC only recommendsTrusted Source mixing vaccines in the following specific circumstances:

  • the preferred vaccine is unavailable
  • there’s no information on the previous dose
  • you would otherwise not receive a recommended vaccine dose
  • you cannot complete the original vaccination series because you had an adverse reaction

As with adults, there isn’t a clear answer as to which vaccine is better for your child.

The CDC recommendsTrusted Source that everyone 6 months old and older be vaccinated against COVID-19. However, given the FDA COVID-19 approval announcement on May 22, 2025, this may change.

Currently, the CDC recommends the Pfizer and Moderna vaccines for children 6 months old and older, whereas Novavax is intended for those 12 years old and olderTrusted Source.

Research shows that the Moderna and Pfizer vaccines are generally safe for children. Lower doses have been deemed safe for children ages 6 months to 5 years.

While children have a higher chance of developing myocarditis (an inflammation of the heart) related to mRNA vaccines, this risk is now considered lowTrusted Source.

According to a 2022 review of studies that investigated the risk of myocarditis, individuals are seven times more likely to experience myocarditis after infection with the virus that causes COVID-19 than after a COVID-19 vaccination. Extending the time between doses to 8 weeks helps improve immune response and reduce the risk of myocarditis even more.

A 2023 clinical study also found that Novavax caused mostly mild adolescent reactions, which were only slightly stronger after the second dose. A follow-up study in 2025 found that the Novavax vaccine was 73.5% effectiveTrusted Source at preventing COVID-19 infection, and those who were vaccinated and then contracted COVID-19 had minimal or no symptoms.

However, since Novavax is still relatively new, more research is needed.

One 2023 studyTrusted Source in Australia found that COVID-19 vaccines were highly effective in preventing deaths among older Australians during the peak of the Omicron variant outbreak in 2022. However, after 6 months of receiving the booster, effectiveness dropped to around 50%.

This highlights the importance of getting additional boosters in this age group, especially those released to target newer virus variants.

Multiple studiesTrusted Source confirm the effectivenessTrusted Source of vaccination in older adults.

When it comes to which is best, a 2023 studyTrusted Source comparing Pfizer and Moderna vaccines in older adults found that the Moderna vaccine was associated with slightly fewer side effects than Pfizer in this age group.

A 2024 study compared mRNA and protein subunit vaccines in Taiwan. Researchers found that in people over 65 years old who were given three vaccine doses, both vaccine types provided comparable protection against death. The effectiveness rates against death were:

  • 86.6% for Moderna
  • 85.2% for Novavax
  • 83.6% for Pfizer

Therefore, which vaccine is preferable to someone in this age group might ultimately be based on personal preference.

People who are immunocompromised have an increased risk of severe illness or death due to COVID-19. This includes people who:

As with adults and children, the CDC now recommendsTrusted Source any of the three vaccine options for immunocompromised people so long as the specific recommendations on age and number of doses are followed.

A 2021 studyTrusted Source examined the effectiveness of two mRNA vaccine doses in immunocompromised people. It found that the Pfizer vaccine was 71% effective, and the Moderna vaccine was 81% effective. However, this difference isn’t considered statistically significant.

That said, a 2022 meta-analysis of 82 studiesTrusted Source found that antibody response rates in immunocompromised people may be lower than in those who are not immunocompromised. This means immunocompromised people usually need more doses to develop enough antibodies against the coronavirus.

However, this study did not examine the Novavax vaccine.

A 2022 review articleTrusted Source also states that an additional dose may raise antibody response rates from 41% to 67%. However, researchers also note there may be significant variation between different groups of immunocompromised people.

A 2023 randomized placebo trialTrusted Source with adults 18 to 84 years old found that Novavax was generally 82.7% effective. It was 100% effective for preventing severe disease. That said, the study didn’t examine how effective it is for immunocompromised participants.

The COVID-19 vaccine schedule for immunocompromised people differs slightly from the schedule for the larger population. The table below shows the CDC’s 2024-25 vaccine recommendationsTrusted Source for immunocompromised individuals.

Be sure to speak with the healthcare professional who gives you your COVID-19 vaccination. They can let you know if you need more than one COVID-19 vaccination and when you need to have it.

Any 2024–25 Pfizer-BioNTech COVID-19 Vaccine:
Pfizer or COMIRNATY
(mRNA vaccines)
Any 2024–25
Moderna
(mRNA vaccine)
2024–25 Novavax
(protein subunit vaccine)
Recommended ages6 months and older6 months and older12 years and older
Primary series3 initial doses:
• dose 1 now (or before)
• dose 2 given at least 3 weeks after dose 1
• dose 3 given at least 4 weeks after dose 2
3 initial doses:
• dose 1 (now or before)
• dose 2 given at least 3 weeks after dose 1
• dose 3 given at least 8 weeks after dose 2
2 initial series:
• dose 1 (now or before)
• dose 2 at least 3 weeks after Dose 1
Booster doseBooster (dose 4):
• typically given 6 months after Dose 3
• in 2025, dose 4 may be administered as soon as 8 weeks after the last dose of the 2024–25 COVID-19 vaccine
Booster (dose 4):
• typically, given 6 months after Dose 3
• in 2025, dose 4 may be administered as soon as 8 weeks after the last dose of the 2024–25 COVID-19 vaccine
Booster (dose 3):
• typically given 6 months after Dose
• in 2025, dose 4 may be administered as soon as 8 weeks after the last dose of the 2024–25 COVID-19 vaccine

To be protected from COVID-19, it’s important to stay current on your COVID-19 vaccines. But what exactly does this mean?

According to the CDCTrusted Source, you’re up to date on your COVID-19 vaccines when you’ve received both your primary vaccine series and your booster dose.

The CDC recommendsTrusted Source that all individuals get the 2024-25 COVID-19 vaccination. They also recommend stopping the use of any COVID-19 vaccination produced prior to the 2024-25 versions.

If you’ve received only your primary vaccine series, you are considered fully vaccinated but not current.

Note that if you have a compromised immune system, your doctor may also recommend taking pemivibart (Pemgarda). The FDA recently authorizedTrusted Source this monoclonal antibody medication in 2024 to help people who may not be able to build enough of an immune response from a vaccine.

Overall, receiving any of the currently available COVID-19 vaccines is better than not getting vaccinated. This is because all of the COVID-19 vaccines are safe and effective at protecting you from serious illness and death due to COVID-19.

The brand and type of vaccine you prefer largely depend on your age, health conditions, and preferences. Talk with your doctor, pharmacist, or other healthcare professional if you have any questions or concerns about your COVID-19 vaccination.